What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.
How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis
Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.
How the Lixte Biotechnology Holdings and dostarlimab study could influence future ovarian cancer trial design
Lixte Biotechnology’s LB-100 ovarian cancer data may signal a new immunotherapy pathway. Read what this could change for the sector.
Could Septerna open a new chapter in disease-modifying hypoparathyroidism treatment?
Could Septerna’s SEP-479 change hypoparathyroidism care? Read how this Phase 1 launch may reshape rare endocrine treatment pathways.
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.
How Veld Pharmaceuticals and Chiesi Farmaceutici are expanding rare disease therapy access in Africa
Chiesi Farmaceutici and Veld Pharmaceuticals expand rare disease therapy access across Africa. Discover what this means for market access and regulation.
What Verrica Pharmaceuticals’ VP-315 data may reveal about the future of skin cancer immunotherapy
Read how Verrica Pharmaceuticals’ VP-315 data could reshape skin cancer immunotherapy and what clinicians and investors should watch next.
How Telix Pharmaceuticals Limited may be building a stronger neuro-oncology diagnostics franchise
Telix Pharmaceuticals Limited’s TLX101-Px NDA has been accepted by the FDA. Discover what this means for glioma imaging and the September decision.
Why Sobi’s EMPAVELI approval in Canada may change the rare kidney disease treatment landscape
Health Canada clears EMPAVELI for C3G and IC-MPGN. Read what this changes for nephrology treatment, market access, and rare kidney disease care.
How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.